A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered
prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and
severity of radiation induced oral mucositis in patients who have been diagnosed with
locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Eligibility Criteria

Inclusion Criteria:

1. Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck,
defined as SCC of the oral cavity or oropharynx that will be treated with cisplatin
plus concurrent IMRT Note: Patients with unknown primary tumors whose treatment plan
matches the requirements specified in Inclusion Criteria #2 and #3 below are eligible
for the trial.

2. Treatment plan to receive a continuous course of IMRT delivered as single daily
fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy.
Planned radiation treatment fields must include at least two oral sites (buccal
mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total
of > 50 Gy. Patients who have had prior surgery are eligible, provided they have
fully recovered from surgery, and patients who may have surgery in the future are

3. Treatment plan to receive standard cisplatin monotherapy administered either every
three weeks (80-100 mg/m2 for 3 doses) or weekly (30-40 mg/m2 for 6-7 doses). The
decision on which chemotherapy regimen to use in combination with IMRT and GC4419
will be at the discretion of the investigator.

4. Age 18 years or older

5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

6. Adequate hematologic function as indicated by:

- Absolute neutrophil counts (ANC) ≥ 1,500/mm3

- Hemoglobin (Hgb) ≥ 9.0 g/dL

- Platelet count ≥ 100,000/mm3

7. Adequate renal and liver function as indicated by:

- Serum creatinine acceptable for treatment with cisplatin per institutional

- Total bilirubin ≤ 1.5 x upper-normal limit (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

- Alkaline phosphatase ≤ 2.5 x ULN

8. Human papilloma virus (HPV) status in tumor has been documented using tumor
immunohistochemistry for HPV-p16 or other accepted test

9. Serum pregnancy test negative for females of childbearing potential

10. Males and females must agree to use effective contraception starting prior to the
first day of treatment and continuing for 30 days after the last dose of GC4419

11. Properly obtained written informed consent

Exclusion Criteria:

1. Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands

2. Metastatic disease (Stage IV C)

3. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or
more than 25% of total body marrow-bearing area (potentially interfering with

4. Prior induction chemotherapy

5. Receiving any approved or investigational anti-cancer agent other than those provided
for in this study

6. Participation in another clinical trial or use of another investigational agent
within 30 days of study entry

7. Requirement for significantly modified diet (liquids and/or solids) due to
compromised oral/pharyngeal function at baseline

8. Requirement at baseline for parenteral or gastrointestinal tube-delivered nutrition
for any reason

9. Malignant tumors other than HNC within the last 5 years, unless treated definitively
and with low risk of recurrence in the judgment of the treating investigator

10. Active infectious disease excluding oral candidiasis

11. Presence of oral mucositis (WHO Score ≥ Grade 1) at study entry

12. Known history of HIV or active hepatitis B/C (patients who have been vaccinated for
hepatitis B and do not have a history of infection are eligible)

13. Female patients who are pregnant or breastfeeding

14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds

15. Requirement for concurrent treatment with nitrates or other drugs that may, in the
judgment of the treating investigator, create a risk for a precipitous decrease in
blood pressure

Principal Investigator

Christopher Lominska, MD

Study Contact

Elisabeth Pauley, BS, RN-BSN, epauley2@kumc.edu, 913-588-0980

Estimated Completion Date

Friday, June 1, 2018

ClinicalTrials.gov #